drugset / Trial / NCT00936390
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Phase 3
Completed
1538 enrolled
Radiation Therapy Oncology Group
NRG Oncology · collabNational Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation therapy is more effective with or without androgen-deprivation therapy in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.
Timeline
- Start
- 2009-09
- Primary completion
- 2020-10-03
- Completion
- 2025-09-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bicalutamide | Other / unclassified | 50 mg | Oral |
| Subject | Degarelix | Other / unclassified | — | — |
| Subject | Goserelin | Other / unclassified | — | — |
| Subject | Leuprolide | Other / unclassified | — | — |
| Subject | Triptorelin | Other / unclassified | — | — |
| Subject | buserelin | Unknown | — | — |
| Subject | flutamide | Small molecule | 250 mg | Oral |